Alliancebernstein L.P. increased its stake in Amylyx Pharmaceuticals by 1.0% during the 3rd quarter.

Source: https://www.americanbankingnews.com/2023/11/12/amylyx-pharmaceuticals-nasdaqamlx-pt-lowered-to-40-00-at-the-goldman-sachs-group.html

Amylyx Pharmaceuticals, a biotech firm focusing on neurodegenerative disorders, has seen impressive Q1 2023 financial performance despite clinical uncertainties around its flagship product, Relyvrio.

Source: https://seekingalpha.com/article/4604493-amylyx-stock-q1-earnings-resilient-performance-market-potential-upgrade-cautious-buy?source=feed_all_articles

HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, February 15th.

Source: https://www.etfdailynews.com/2023/03/01/amylyx-pharmaceuticals-inc-nasdaqamlx-major-shareholder-sells-1736500-00-in-stock/

Hennion & Walsh Asset Management Inc. acquired a new position in shares of Amylyx Pharmaceuticals, Inc. () in the 4th quarter, reports.

Source: https://www.etfdailynews.com/2023/03/25/16956-shares-in-amylyx-pharmaceuticals-inc-nasdaqamlx-acquired-by-hennion-walsh-asset-management-inc/

Two months later, the F.D.A. reversed its position, and invited Amylyx to submit its application.

Source: https://www.newyorker.com/magazine/2023/06/26/relyvrio-als-fda-approval

Wells Fargo & Company MN lifted its position in shares of Amylyx Pharmaceuticals by 79.6% during the 4th quarter.

Source: https://www.etfdailynews.com/2023/12/16/amylyx-pharmaceuticals-nasdaqamlx-now-covered-by-deutsche-bank-aktiengesellschaft/